Biogen wins another big Tecfidera patent case

For the second time in as many weeks, Biogen has prevailed in a high-stakes legal dispute over patents on its blockbuster multiple sclerosis treatment Tecfidera.

The U.S. Patent Trial and Appeal Board on Friday rejected a bid by Danish biotech Forward Pharma (Nasdaq: FWP) to invalidate the patents. A ruling in favor of Forward Pharma would have forced Biogen (Nasdaq: BIIB) to pay a 10 percent royalty on sales of Tecfidera beginning in 2021.

In January, Biogen agreed to pay Forward Pharma $1.25 billion to license the Danish company’s intellectual property. For the Cambridge drugmaker, the settlement was essentially an insurance policy against a potential loss in the case.

Full Story Here

1 Comment

  1. It was actually amazing to read this info and I believe you’re completely right. Tell me in the event that you are curious about omega xl rating, that is my major competence. I’m hoping to hear from you soon enough, cheers!


Submit a Comment

Your email address will not be published.

Subscribe to get the latest news